Pre-market Hot Trades in US Stocks
Intercont, down 7.88% in pre-market trading, has no significant news recently. Trading is active with clear capital flow; considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.
Founder is down 7.46% in pre-market trading. Based on recent key news:
<ol>
<li>
On March 27, Founder announced the cancellation of a buyback of 400,000 shares, putting pressure on the stock price. The buyback price was HKD 0.8 per share, leading to a 0.0346% reduction in circulating shares, raising market concerns about the company's financial strategy, resulting in a stock price decline.
</li>
<li>
On March 26, Founder signed an EPC contract worth approximately USD 8.6 million, causing stock price fluctuations. This contract pertains to a large solar project in Malaysia; despite the large contract amount, it failed to boost the stock price, reflecting market concerns about the project's profitability.
</li>
<li>
On March 25, Founder announced an additional contract worth USD 8.6 million, with no significant boost to the stock price. The market remains cautious about the long-term benefits of the contract, leading to continued pressure on the stock price. The solar industry has been volatile recently and requires attention.
</li>
</ol>
Top Gainers in Pre-market US Stocks
Artelo Biosciences is up 154.86% in pre-market trading. Based on recent key news:
<ol>
<li>
On March 27, Artelo Biosciences announced the withdrawal of its SEC registration statement, as the company currently has no intention of selling securities. This move is interpreted by the market as a cautious attitude towards the capital market, driving a significant increase in stock price.
</li>
<li>
On March 25, Artelo Biosciences released news via GlobeNewswire, emphasizing the strategic positioning and capital efficiency of its three clinical projects. The company's diversification strategy is seen as a positive signal for long-term growth, boosting investor confidence.
</li>
<li>
On March 24, Artelo Biosciences filed documents in the EDGAR system, further disclosing its business development plans, increasing market expectations for its future growth potential. The biopharmaceutical industry has been active recently, attracting investor attention to growth potential.
</li>
</ol>
Hitek Global Inc. is up 69.48% in pre-market trading. Based on recent key news:
<ol>
<li>
On March 27, HiTek Global announced that Maxim terminated the company's market sales agreement. Under this agreement, 5,852,011 shares of Class A common stock have been sold, raising market concerns about the company's future financing capabilities, leading to significant stock price fluctuations. Source: EDGAR system disclosure.
</li>
<li>
On March 25, Rosen Law Firm encouraged HiTek Global investors to consult regarding a collective securities lawsuit investigation. This move may increase the legal risks faced by the company, affecting investor confidence. Source: Rosen Law Firm
</li>
<li>
Recently, there are no other important news. The market's attention to legal risks has increased.
</li>
</ol>
Onconetix pre-market rose 63.98%. Based on recent news,
<ol>
<li>
On March 25, Onconetix announced a 1-for-5 reverse stock split aimed at boosting the stock price and re-compliance with Nasdaq listing standards. This move led to a 55.59% increase in the stock price during pre-market trading.
</li>
<li>
On March 27, Onconetix completed the acquisition of Realbotix, which is believed to bring significant value to the company and further drive up the stock price.
</li>
<li>
On March 18, Onconetix appointed David White as the new CEO, and the market's expectations for the new leadership have also positively impacted the stock price. The stock performed strongly in the short term, but long-term challenges remain
</li>
</ol>

Intercont pre-market down 7.88%; Founder pre-market down 7.46%; Artelo Biosciences pre-market up 154.86%; Hitek Global Inc. pre-market up 69.48%; Onconetix pre-market up 63.98%

Pre-market hot trades in US stocks: Intercont pre-market down 7.88%; Founder pre-market down 7.46%